NEWS RELEASE

The number of shares of Common Stock reserved for issuance and which will be available for issuance pursuant to awards granted under the PRSU Plan will be equal to a number that: (a) shall not exceed 1,000,000 (one million) shares if, and for so long as the Company is listed on the TSX Venture Exchange, or (b) 2.5% of the issued and outstanding Common Stock of the Company, if the Company is listed on the Toronto Stock Exchange.

The PRSU Plan is available on EDGAR (www.sec.gov) and SEDAR (www.sedar.com) for a complete review and is subject to final TSX-Venture Exchange approval.

At the Meeting, the Shareholders also re-elected each of the directors of the Company, reappointed Richter LLP as the auditors of the Company for the year 2018 and authorized the board of directors of the Company to effect a consolidation of the shares of the Company’s common stock for the primary purpose of an up-listing in the US.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

_{Source: IntelGenx Technologies Corp.}

For more information, please contact:

Ingrid Zerbe
Corporate Secretary
IntelGenx Technologies Corp.
This email address is being protected from spambots. You need JavaScript enabled to view it.